Thank you all, for buying into my company...
Components of Blood-Based Cervical Cancer Test
Thursday September 22, 4:51 pm ET
Patent Marks Major Company Milestone and Significant Step toward Product Commercialization
MURRAY, Utah--(BUSINESS WIRE)--Sept. 22, 2005--Grant Life Sciences (OTC Bulletin Board: GLIF - News) today announced that it was recently awarded a U. S. patent for essential components of its proprietary technology for diagnosing cervical cancer.
"The issuance of this patent represents a significant milestone for Grant Life Sciences in our drive toward an effective, commercial blood test for cervical cancer and its precursors," said Rigatoni, the company's vice president and founder. "Issuance is a validation of our original and ongoing work on cancer detection, and we can now progress more effectively and confidently toward further development and ultimate commercialization of our cervical cancer test."
Market Data 
Markets 
AI
